Clinical Commander

Back to dossier
cardio.cardiogenic-shock.acute-aortic-regurgitation.v1PRODUCTION
cardio.cardiogenic-shock.acute-aortic-regurgitation.v1

Cardiogenic shock — acute severe aortic regurgitation

cardiologyacuteadult
Hard-required inputs
0 / 16
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm acute severe AR as the cardiogenic shock etiology — sudden flash pulm edema + new diastolic murmur + biventricular dysfunction + NARROW pulse pressure (opposite to chronic AR); identify suspected sub-etiology (Type A dissection vs endocarditis vs trauma vs iatrogenic) which drives surgical urgency; CTA chest is mandatory rule-out for dissection

Inputs
2
Actions
0
Advance rule
Set
Advance when

Acute severe AR confirmed and dissection screened

Patient inputs (19)

GOLD STANDARD — vena contracta ≥0.6 cm, holodiastolic flow reversal in descending aorta, PHT <250 ms (severe), cusp tear / perforation / dissection flap visualization, paravalvular abscess if endocarditis

MANDATORY rule-out of Stanford Type A aortic dissection (most common life-threatening etiology); identifies extension to root + branch involvement

Younger patients (Marfan, Ehlers-Danlos, bicuspid valve) over-represented in spontaneous cusp rupture; older patients in dissection / endocarditis; informs surgical-risk + connective tissue evaluation

COMPENSATORY TACHYCARDIA maintains forward flow in acute AR — DO NOT suppress with β-blocker pre-surgery (diastolic prolongation worsens regurgitation)

NARROW pulse pressure in acute AR (opposite to chronic AR wide pulse pressure) — cardinal hemodynamic finding

End-organ damage marker + dose adjustment for nitroprusside (cyanide accumulation); contrast nephropathy risk for CTA

Flash pulmonary edema severity tracker; intubation often needed

Elevated if etiology is dissection extending to coronary ostium or concurrent ischemia

Aortic dissection screen — markedly elevated D-dimer raises pretest probability for dissection

Acute volume overload marker; trend tracks decongestion + recovery

Active endocarditis is a major etiology of acute AR; obtain × 3 sets before any antibiotics

Bedside TTE for initial screen — diastolic mitral valve closure (M-mode), AR jet, biventricular function; PRELIMINARY only — TEE is gold standard

Sinus tachycardia (compensatory) + LV strain; STEMI pattern if dissection extending to coronary ostium

Flash pulmonary edema + normal or mildly dilated cardiac silhouette + widened mediastinum if dissection

SCAI 2022 staging baseline; gates vasopressor escalation; SBP <90 with flash pulm edema is the cardinal acute AR + CS presentation

SCAI 2022 staging + response to therapy; CardShock prognostication (Harjola EHJ 2015 PMID 26333869)

Pre-existing bicuspid aortic valve, prior aneurysm, connective tissue disease (Marfan, Ehlers-Danlos), prior aortic surgery

Blunt chest trauma → leaflet tear / commissural disruption

Recent TAVR (paravalvular leak) / balloon valvuloplasty / surgical valve manipulation

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningaortic_dissection_extending_to_root_with_severe_ar
    Stanford Type A aortic dissection on CTA extending to root with cusp prolapse + acute severe AR + cardiogenic shock — concurrent surgical emergency (aortic + valve)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningbeta_blocker_exposure_error_in_acute_severe_ar_pre_surgery
    β-blocker administered before surgery in acute severe AR — suppresses compensatory tachycardia, worsens forward flow, may precipitate shock — STOP and resuscitate; chronotropic support if needed; expedite surgery
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningiabp_placement_error_in_acute_severe_ar
    IABP placed in acute severe AR — diastolic augmentation INCREASES regurgitant volume, worsens hemodynamics — REMOVE IMMEDIATELY; switch to nitroprusside afterload reduction + dobutamine inotrope; expedite surgery
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningendocarditis_with_acute_ar_and_paravalvular_abscess
    Active infective endocarditis (S. aureus, Strep) + acute severe AR + paravalvular abscess on TEE + cardiogenic shock — emergent surgery indication despite operative risk; high mortality without surgery
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereflash_pulmonary_edema_refractory_in_acute_severe_ar
    Refractory flash pulmonary edema in acute severe AR despite nitroprusside + diuretic + dobutamine — intubation needed; expedite surgery; cyanide toxicity risk if prolonged nitroprusside
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Acute severe AR + CS — emergent surgery + nitroprusside afterload reduction (cornerstone) + dobutamine inotrope + intubation often needed; AVOID IABP (worsens AR) + AVOID β-blocker pre-surgery (suppresses compensatory tachycardia)
axis: acute_severe_ar_cs_phenotype
Selected axis "Acute severe AR + CS — emergent surgery + nitroprusside afterload reduction (cornerstone) + dobutamine inotrope + intubation often needed; AVOID IABP (worsens AR) + AVOID β-blocker pre-surgery (suppresses compensatory tachycardia)" by default fallback (first axis)
  • sodium nitroprusside
    first line
    arteriovenodilator
    0.25–0.5 µg/kg/min start; titrate to MAP 65–75 (max 10 µg/kg/min for ≤10 min) • IV • continuous
    triggers: acute_severe_ar_with_adequate_map, need_afterload_reduction_to_reduce_regurgitant_fraction
    CORNERSTONE pharmacologic bridge in acute severe AR — reduces SVR → reduces regurgitant fraction → improves forward flow + reduces pulmonary edema; cyanide accumulation risk if eGFR <30 (use sodium thiosulfate co-infusion for prolonged use)
    rxcui 9895
  • dobutamine
    first line
    inotrope_beta1
    2.5–5 µg/kg/min titrate • IV • continuous
    triggers: low_cardiac_output_in_acute_ar, need_inotropic_support_pre_surgery
    Preferred over pressors that increase SVR (which worsens AR); supports forward flow + maintains MAP via β1 inotropy without major SVR rise; DOREMI PMID 33704937
    rxcui 3616
  • norepinephrine
    second line
    vasopressor_alpha
    0.05 µg/kg/min start; minimize doses • IV • continuous
    triggers: refractory_hypotension_despite_dobutamine_and_nitroprusside, need_map_above_65
    CAUTION — increases SVR which worsens AR severity; use lowest dose to maintain MAP ≥65; SOAP-II PMID 20200382 generally first-line in CS but in acute AR is second-line behind dobutamine + nitroprusside
    rxcui 7512
  • furosemide
    first line
    loop_diuretic
    40–80 mg IV bolus then infusion 5–10 mg/h • IV • bolus + continuous
    triggers: flash_pulmonary_edema, volume_overload_with_adequate_perfusion
    Decongest after perfusion stable (ESC 2021 HF Guidelines); continuous infusion preferred for refractory pulm edema
    rxcui 4603
  • vancomycin
    first line
    glycopeptide_antibiotic
    25–30 mg/kg IV load then 15–20 mg/kg q12h adjusted to trough 15–20 • IV • q12h
    triggers: endocarditis_suspected_in_acute_ar, awaiting_blood_culture_results
    AHA 2015 endocarditis guideline empiric coverage for native valve endocarditis — gram-positive cocci dominant pathogen spectrum (Baddour PMID 26373316)
    rxcui 11124
  • ceftriaxone
    first line
    cephalosporin_3rd_gen
    2 g IV q24h • IV • q24h
    triggers: endocarditis_suspected_in_acute_ar, awaiting_blood_culture_results
    AHA 2015 endocarditis guideline empiric coverage — covers Streptococcus + HACEK organisms
    rxcui 2193
  • warfarin
    first line
    vitamin_k_antagonist
    Post-op: 5 mg daily; mechanical aortic INR target 2.0–3.0; bioprosthetic INR 2–3 × 3 mo then ASA • PO • daily
    triggers: mechanical_aortic_valve_post_op, bioprosthetic_aortic_valve_first_3_mo
    ACC/AHA 2020 valvular Class I — mechanical aortic valve INR 2.0–3.0 (vs mitral 2.5–3.5); bioprosthetic INR 2–3 × 3 mo then ASA chronic
    rxcui 11289
  • esmolol (CAUTIOUS — only if dissection BP control absolutely required)
    rescue
    beta1_selective_blocker
    500 µg/kg load, then 50 µg/kg/min titrate; AVOID generally • IV • continuous
    triggers: concurrent_type_a_dissection_with_uncontrolled_hypertension_AND_surgery_imminent_within_minutes
    CAUTION — β-blocker suppresses compensatory tachycardia in acute AR → worsens forward flow; reserve for dissection BP control when surgery is imminent and BP cannot be controlled by nitroprusside alone
    rxcui 203222

outpatient playbook — drug actions (5)

  1. 1. continue warfarin lifelong (mechanical aortic) or × 3 mo (bioprosthetic)
    rxcui 11289
    INR 2.0–3.0 mechanical aortic / 2–3 × 3 mo bioprosthetic • PO • daily
    trigger: Post-op valve replacement
    ACC/AHA 2020 valvular Class I — lifelong for mechanical aortic, 3 mo + ASA chronic for bioprosthetic
  2. 2. continue or up-titrate GDMT 4-pillar if persistent EF<40
    lisinopril or sac/val + carvedilol + MRA + SGLT2i • PO • daily/BID
    trigger: Persistent EF<40
    AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499)
  3. 3. continue aspirin 81 mg if bioprosthetic
    rxcui 243670
    81 mg PO daily • PO • daily
    trigger: Bioprosthetic AV
    ACC/AHA 2020 valvular Class IIa lifelong
  4. 4. amoxicillin 2 g 30-60 min before dental procedures
    2 g PO • PO • before procedure
    trigger: Prosthetic valve + dental procedure with bleeding risk
    AHA 2007 endocarditis prophylaxis
  5. 5. metoprolol succinate or losartan for aortopathy
    rxcui 6918
    metoprolol 25–100 mg daily; losartan 25–100 mg daily for Marfan per Lacro PEDIATRIC trial • PO • daily
    trigger: Dissection / aortopathy / Marfan
    Erbel ESC 2014 aortic dissection guideline (PMID 25173340); PEDIATRIC HEART NETWORK Marfan trial Lacro NEJM 2014

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Sudden chest / back pain + new diastolic murmur + flash pulmonary edema + cardiogenic shock → acute severe AR with concurrent dissection until proven otherwise; STAT TEE: vena contracta ≥0.6 cm, holodiastolic flow reversal in descending aorta, premature mitral valve closure on M-mode, PHT <250 ms + biventricular dysfunction + shock physiology; CTA chest: Stanford Type A aortic dissection extending into root with cusp prolapse + acute severe AR + cardiogenic shock — concurrent surgical emergency.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — acute severe aortic regurgitation** (cardio.cardiogenic-shock.acute-aortic-regurgitation.v1).
Scope: Confirm acute severe AR as the cardiogenic shock etiology — sudden flash pulm edema + new diastolic murmur + biventricular dysfunction + NARROW pulse pressure (opposite to chronic AR); identify suspected sub-etiology (Type A dissection vs endocarditis vs trauma vs iatrogenic) which drives surgical urgency; CTA chest is mandatory rule-out for dissection

No severity triggers fired against current inputs.

Plan

Regimen axis: **Acute severe AR + CS — emergent surgery + nitroprusside afterload reduction (cornerstone) + dobutamine inotrope + intubation often needed; AVOID IABP (worsens AR) + AVOID β-blocker pre-surgery (suppresses compensatory tachycardia)**.
1. sodium nitroprusside 0.25–0.5 µg/kg/min start; titrate to MAP 65–75 (max 10 µg/kg/min for ≤10 min) IV continuous (arteriovenodilator, first line) — CORNERSTONE pharmacologic bridge in acute severe AR — reduces SVR → reduces regurgitant fraction → improves forward flow + reduces pulmonary edema; cyanide accumulation risk if eGFR <30 (use sodium thiosulfate co-infusion for prolonged use)
2. dobutamine 2.5–5 µg/kg/min titrate IV continuous (inotrope_beta1, first line) — Preferred over pressors that increase SVR (which worsens AR); supports forward flow + maintains MAP via β1 inotropy without major SVR rise; DOREMI PMID 33704937
3. norepinephrine 0.05 µg/kg/min start; minimize doses IV continuous (vasopressor_alpha, second line) — CAUTION — increases SVR which worsens AR severity; use lowest dose to maintain MAP ≥65; SOAP-II PMID 20200382 generally first-line in CS but in acute AR is second-line behind dobutamine + nitroprusside
4. furosemide 40–80 mg IV bolus then infusion 5–10 mg/h IV bolus + continuous (loop_diuretic, first line) — Decongest after perfusion stable (ESC 2021 HF Guidelines); continuous infusion preferred for refractory pulm edema
5. vancomycin 25–30 mg/kg IV load then 15–20 mg/kg q12h adjusted to trough 15–20 IV q12h (glycopeptide_antibiotic, first line) — AHA 2015 endocarditis guideline empiric coverage for native valve endocarditis — gram-positive cocci dominant pathogen spectrum (Baddour PMID 26373316)
6. ceftriaxone 2 g IV q24h IV q24h (cephalosporin_3rd_gen, first line) — AHA 2015 endocarditis guideline empiric coverage — covers Streptococcus + HACEK organisms
7. warfarin Post-op: 5 mg daily; mechanical aortic INR target 2.0–3.0; bioprosthetic INR 2–3 × 3 mo then ASA PO daily (vitamin_k_antagonist, first line) — ACC/AHA 2020 valvular Class I — mechanical aortic valve INR 2.0–3.0 (vs mitral 2.5–3.5); bioprosthetic INR 2–3 × 3 mo then ASA chronic
8. esmolol (CAUTIOUS — only if dissection BP control absolutely required) 500 µg/kg load, then 50 µg/kg/min titrate; AVOID generally IV continuous (beta1_selective_blocker, rescue) — CAUTION — β-blocker suppresses compensatory tachycardia in acute AR → worsens forward flow; reserve for dissection BP control when surgery is imminent and BP cannot be controlled by nitroprusside alone

Setting playbook (outpatient) — 1 mo + 3 mo + 6 mo + annual valve + aortic clinic surveillance — confirm valve function + LV recovery + INR control + GDMT optimization + endocarditis prophylaxis + aortic surveillance + lifelong follow-up
9. continue warfarin lifelong (mechanical aortic) or × 3 mo (bioprosthetic) INR 2.0–3.0 mechanical aortic / 2–3 × 3 mo bioprosthetic PO daily — Post-op valve replacement (ACC/AHA 2020 valvular Class I — lifelong for mechanical aortic, 3 mo + ASA chronic for bioprosthetic)
10. continue or up-titrate GDMT 4-pillar if persistent EF<40 lisinopril or sac/val + carvedilol + MRA + SGLT2i PO daily/BID — Persistent EF<40 (AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499))
11. continue aspirin 81 mg if bioprosthetic 81 mg PO daily PO daily — Bioprosthetic AV (ACC/AHA 2020 valvular Class IIa lifelong)
12. amoxicillin 2 g 30-60 min before dental procedures 2 g PO PO before procedure — Prosthetic valve + dental procedure with bleeding risk (AHA 2007 endocarditis prophylaxis)
13. metoprolol succinate or losartan for aortopathy metoprolol 25–100 mg daily; losartan 25–100 mg daily for Marfan per Lacro PEDIATRIC trial PO daily — Dissection / aortopathy / Marfan (Erbel ESC 2014 aortic dissection guideline (PMID 25173340); PEDIATRIC HEART NETWORK Marfan trial Lacro NEJM 2014)

Non-pharmacologic actions:
- Cardiac rehab maintenance phase
- Annual influenza + pneumococcal + COVID-19 vaccination
- Dental cleanings q6 mo with endocarditis prophylaxis
- Valve clinic + aortic clinic lifelong follow-up
- Pregnancy counseling (mechanical valve + warfarin teratogenicity; aortopathy + pregnancy risk)
- Genetic counseling for connective tissue disease

AVOID / contraindication checks:
- IABP_AVOID_in_acute_severe_ar (diastolic augmentation INCREASES regurgitant volume; CONTRAINDICATED)
- Beta_blocker_AVOID_pre_surgery_in_acute_ar (loss of compensatory tachycardia worsens forward flow)
- Beta_blocker_AVOID_in_cardiogenic_shock (ACC/AHA 2022)
- Isolated_high_dose_vasoconstrictor_AVOID_in_acute_ar (SVR rise worsens regurgitant fraction)
- Nitroprusside_cyanide_risk_if_egfr_lt_30 (use sodium thiosulfate cofactor; alternative agents preferred)
- LV_only_Impella_complex_in_acute_ar (limited evidence; valve crossing risk; surgery is the definitive treatment)
- Routine_VA_ECMO_AVOID_in_acute_ar (VA ECMO retrograde aortic flow may worsen AR; surgery is definitive)
- Doac_AVOID_in_mechanical_valve (warfarin only per ACC/AHA 2020)
- Nsaids_AVOID_in_active_decompensation (worsen renal function + fluid retention)

Monitoring

Regimen monitoring:
- arterial line continuous BP (ACC/AHA 2022 Class I)
- central venous access (ACC/AHA 2022)
- lactate q1-2h (CardShock, Harjola EHJ 2015)
- UOP hourly (SCAI 2019 end-organ perfusion marker)
- serial echo q12-24h post op for valve function (ACC/AHA 2020 valvular)
- continuous telemetry for arrhythmia
- daily BNP and troponin (trend tracks recovery)
- INR daily during warfarin initiation post op (target per valve type — aortic 2.0–3.0)
- blood cultures serial if endocarditis (sterilization tracking)
- cyanide monitoring if prolonged nitroprusside use (ABG, lactate, mental status)
- aortic surveillance imaging if dissection or connective tissue disease

Setting (outpatient) monitoring:
- Echo at 1 mo + 3 mo + 6 mo + annually
- INR per protocol
- BMP + lipid annually
- Aortic CTA / MRA per dissection surveillance schedule

Follow-up plan: Repeat TTE at 1 wk + 1 mo + 3 mo post-surgery for valve function + LV recovery; cardiac rehab; GDMT if persistent HFrEF; endocarditis prophylaxis per AHA 2007 if prosthetic valve; lifelong follow-up at valve clinic; long-term anticoagulation per valve type (mechanical = warfarin INR 2-3 aortic; bioprosthetic = ASA + 3 mo warfarin + ASA chronic); aortic surveillance imaging if dissection / connective tissue disease
- Close-out criterion: Recovery echo, valve clinic follow-up, GDMT, long-term anticoag, aortic surveillance plan booked

Monitoring phase: A-line, central line, lactate clearance, urine output; continuous telemetry; serial echo q12-24h post-surgery for valve function + LV recovery; daily BNP; pre-op TEE + intra-op TEE for surgical assessment; CTA reassessment if dissection

Disposition

Current setting: outpatient — 1 mo + 3 mo + 6 mo + annual valve + aortic clinic surveillance — confirm valve function + LV recovery + INR control + GDMT optimization + endocarditis prophylaxis + aortic surveillance + lifelong follow-up

Disposition criteria:
- Stable valve function + LVEF preserved + aortic dimensions stable → annual valve + aortic clinic follow-up
- Persistent HFrEF → long-term cross-link to cardio.hfref.core.v1 / cardio.hf.core.v1

Escalation triggers (move to higher acuity):
- Symptomatic prosthetic valve dysfunction → emergent valve clinic
- New murmur → echo + valve clinic
- Fever with prosthetic valve → ED + endocarditis workup
- Bleeding on warfarin → ED + reversal
- New chest / back pain on aortic surveillance → emergent CTA

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Stanford Type A aortic dissection on CTA extending to root with cusp prolapse + acute severe AR + cardiogenic shock — concurrent surgical emergency (aortic + valve)
- [LIFE_THREATENING] β-blocker administered before surgery in acute severe AR — suppresses compensatory tachycardia, worsens forward flow, may precipitate shock — STOP and resuscitate; chronotropic support if needed; expedite surgery
- [LIFE_THREATENING] IABP placed in acute severe AR — diastolic augmentation INCREASES regurgitant volume, worsens hemodynamics — REMOVE IMMEDIATELY; switch to nitroprusside afterload reduction + dobutamine inotrope; expedite surgery

Citations

- Otto et al ACC/AHA 2020 valvular heart disease guideline (PMID 33342587); Vahanian ESC 2021 valvular heart disease (PMID 34453165); Erbel et al ESC 2014 aortic dissection guidelines (PMID 25173340); Baddour AHA 2015 endocarditis guideline (PMID 26373316); SCAI 2022 CS staging (Naidu PMID 35718438) [PMID:33342587](https://pubmed.ncbi.nlm.nih.gov/33342587/)
- Cited evidence (PMID 34453165) [PMID:34453165](https://pubmed.ncbi.nlm.nih.gov/34453165/)
- Cited evidence (PMID 25173340) [PMID:25173340](https://pubmed.ncbi.nlm.nih.gov/25173340/)
- Cited evidence (PMID 26373316) [PMID:26373316](https://pubmed.ncbi.nlm.nih.gov/26373316/)
- Cited evidence (PMID 35718438) [PMID:35718438](https://pubmed.ncbi.nlm.nih.gov/35718438/)

Last reconciled with current guidelines: 2026-05-15.
References
  • Otto et al ACC/AHA 2020 valvular heart disease guideline (PMID 33342587); Vahanian ESC 2021 valvular heart disease (PMID 34453165); Erbel et al ESC 2014 aortic dissection guidelines (PMID 25173340); Baddour AHA 2015 endocarditis guideline (PMID 26373316); SCAI 2022 CS staging (Naidu PMID 35718438) — PMID:33342587
  • Cited evidence (PMID 34453165) — PMID:34453165
  • Cited evidence (PMID 25173340) — PMID:25173340
  • Cited evidence (PMID 26373316) — PMID:26373316
  • Cited evidence (PMID 35718438) — PMID:35718438